Ascendis Pharma A (ASND) EBITDA (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of EBITDA data on file, last reported at $29.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 126.5% year-over-year to $29.0 million; the trailing twelve-month figure through Mar 2026 stood at -$6.5 million (down 100.0% YoY), and the FY2025 full-year result was -$158.6 million, up 47.43% from the prior year.
• EBITDA grew to $29.0 million in Q1 2026, from $11.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $409.3 billion in Q4 2024 to a low of -$154.2 million in Q1 2023.
• A 5-year average of $24.0 billion and a median of -$109.6 million in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 1039121.01% in 2024 and tumbled 105.32% in 2025, its largest moves.
• Tracing ASND's EBITDA over 5 years: stood at -$150.4 million in 2022, then surged by 73.8% to -$39.4 million in 2023, then jumped by 1039121.01% to $409.3 billion in 2024, then tumbled by 100.0% to $11.5 million in 2025, then surged by 152.17% to $29.0 million in 2026.
• Business Quant data shows ASND's EBITDA at $29.0 million in Q1 2026, $11.5 million in Q4 2025, and $12.9 million in Q3 2025.